Market Cap | 684.88M | P/E | - | EPS this Y | 53.50% | Ern Qtrly Grth | - |
Income | -58.68M | Forward P/E | -5.21 | EPS next Y | -8.50% | 50D Avg Chg | -1.00% |
Sales | 32.02M | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -21.00% |
Dividend | N/A | Price/Book | 3.68 | EPS next 5Y | 74.40% | 52W High Chg | -49.00% |
Recommedations | 3.00 | Quick Ratio | 7.11 | Shares Outstanding | 71.34M | 52W Low Chg | 68.00% |
Insider Own | 2.64% | ROA | -25.96% | Shares Float | 55.21M | Beta | 0.22 |
Inst Own | 77.67% | ROE | -37.43% | Shares Shorted/Prior | 1.71M/1.80M | Price | 9.69 |
Gross Margin | -173.29% | Profit Margin | -183.29% | Avg. Volume | 602,043 | Target Price | 1.55 |
Oper. Margin | -457.48% | Earnings Date | Nov 4 | Volume | 227,498 | Change | -1.22% |
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
HC Wainwright & Co. | Neutral | Sep 17, 24 |
HC Wainwright & Co. | Neutral | Aug 19, 24 |
HC Wainwright & Co. | Neutral | Jul 22, 24 |
HC Wainwright & Co. | Neutral | Jan 22, 24 |
BTIG | Neutral | Jan 11, 24 |
HC Wainwright & Co. | Buy | Dec 29, 23 |
Stifel | Hold | Dec 18, 23 |
HC Wainwright & Co. | Buy | Nov 14, 23 |
Cantor Fitzgerald | Neutral | Nov 14, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Monahan Joseph | Chief Scientific Off.. Chief Scientific Officer | Oct 23 | Sell | 5.0767 | 6,000 | 30,460 | 129,724 | 10/25/23 |
Manion Douglas J. | Pres and CEO Pres and CEO | Mar 09 | Buy | 7.735 | 6,500 | 50,278 | 6,500 | 03/09/23 |
Walker Neal | Director Director | Mar 01 | Sell | 12.5 | 59,240 | 740,500 | 1,273,202 | 03/03/23 |
Monahan Joseph | Chief Scientific Off.. Chief Scientific Officer | Mar 01 | Sell | 12.5 | 30,837 | 385,462 | 147,724 | 03/03/23 |
Balthaser Kevin | Chief Financial Offi.. Chief Financial Officer | Mar 01 | Sell | 12.46 | 1,894 | 23,599 | 5,256 | 03/03/23 |
SCHIFF ANDREW N | Director Director | Nov 10 | Sell | 17.05 | 53,926 | 919,438 | 434,455 | 11/14/22 |
SCHIFF ANDREW N | Director Director | Oct 04 | Sell | 16.27 | 45,539 | 740,920 | 588,916 | 10/06/22 |
SCHIFF ANDREW N | Director Director | Jun 17 | Sell | 15.1428 | 19,565 | 296,269 | 06/21/22 | |
Walker Neal | President and CEO President and CEO | Apr 21 | Sell | 15.15 | 70,000 | 1,060,500 | 1,245,763 | 04/25/22 |
Monahan Joseph | Chief Scientific Off.. Chief Scientific Officer | Apr 18 | Sell | 16.2766 | 30,000 | 488,298 | 106,386 | 04/20/22 |
Walker Neal | President and CEO President and CEO | Mar 11 | Sell | 15.9147 | 56,303 | 896,045 | 1,315,763 | 03/14/22 |
Ruffo Frank | Chief Financial Offi.. Chief Financial Officer | Mar 10 | Sell | 15.5451 | 12,823 | 199,335 | 201,883 | 03/14/22 |
Gordon David N. | Chief Medical Office.. Chief Medical Officer | Jun 02 | Sell | 22.51 | 51,914 | 1,168,584 | 144,078 | 06/02/21 |
Ali-Jackson Kamil | Chief Legal Officer Chief Legal Officer | Jun 02 | Sell | 22.32 | 45,119 | 1,007,056 | 131,688 | 06/02/21 |
Monahan Joseph | Chief Scientific Off.. Chief Scientific Officer | Jun 02 | Sell | 21.91 | 21,790 | 477,419 | 85,342 | 06/02/21 |
Ruffo Frank | Chief Financial Offi.. Chief Financial Officer | Jun 02 | Sell | 21.91 | 15,037 | 329,461 | 169,872 | 06/02/21 |
Walker Neal | President and CEO President and CEO | Jun 02 | Sell | 21.9 | 33,260 | 728,394 | 1,232,182 | 06/02/21 |
Ali-Jackson Kamil | Chief Legal Officer Chief Legal Officer | May 07 | Option | 10.66 | 20,416 | 217,635 | 149,034 | 05/07/21 |
Ali-Jackson Kamil | Chief Legal Officer Chief Legal Officer | May 07 | Sell | 23.6 | 20,416 | 481,818 | 143,618 | 05/07/21 |
Ruffo Frank | Chief Financial Offi.. Chief Financial Officer | Apr 26 | Sell | 26.61 | 87,339 | 2,324,091 | 151,720 | 04/26/21 |
Mehra Anand | Director Director | Feb 03 | Option | 18.34 | 14,632 | 268,351 | 30,841 | 02/03/21 |